Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in interests in American Depositary Shares (ADS).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific equity transaction rather than a financial performance report.
Material Changes
The material change disclosed is an increase in the ADS holdings of a connected person:
- Executive Director: Dr. M. Slaoui
- Connected Person: Mrs. K. Slaoui
- Transaction Type: Award under the GlaxoSmithKline 2009 Performance Share Plan
- Quantity: 2,030 ADS
- Valuation Basis: US$46.21 per ADS (closing price on NYSE, February 11, 2015)
Guidance, Outlook, and Risks
The filing does not contain management guidance, outlook, or general risk factors. The specific contingency noted is that the vesting of the awarded shares is subject to meeting performance criteria over a three-year period. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Checklist
- Verify the vesting schedule and specific performance criteria attached to the 2009 Performance Share Plan.
- Confirm the total aggregate holdings of Dr. M. Slaoui and Mrs. K. Slaoui following this transaction.
- Review the company's annual report (Form 20-F) for comprehensive financial data not included in this transaction notice.